Skip to main content
Industry News
Antabio receives $4.4M grant to continue development of CF antibiotic

CARB-X, a global non-profit partnership, awarded Antabio with a $4.4 million grant to continue developing a novel antibiotic to treat Pseudomonas infections in cystic fibrosis patients. The money is the second installment from a grant awarded to Antabio in 2017.

Full Story: